Placebo practice trials: A tools to assess and improve adherence readiness

HIV Clinical Trials

Volumn 3, Issue 6, 2002, Pages 475-481

  Wagner, Glenn ^a   Iguchi, Martin ^a   Schneider, Stephan ^b   Scott, James ^c   Anderson, David ^c  

^a RAND CORPORATION   (United States)

^b ST MARY MEDICAL CENTER   (United States)

^c LOS ANGELES LGBT CENTER   (United States)

Author keywords

Adherence readiness; Electronic monitoring; HIV

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; ETHNIC OR RACIAL ASPECTS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT MONITORING; PRIORITY JOURNAL; SOCIAL STATUS; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CALIFORNIA; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PILOT PROJECTS; PLACEBOS;

EID: 0036863441     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/WQRY-FNUL-VNE1-56XA     Document Type: Article

References (24)

1. Cozzi Lepri A, Phillips AN, et al. When to start highly active antiretroviral therapy in chronically HIV-infected patients: Evidence from the ICONA study. AIDS. 2001;15:983-990.
2. Hogg RS, Yip B, Wood E, et al. Diminished effectiveness of antiretroviral therapy among patients initiating therapy with CD4 cell counts below 200/cu.mm. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; 2001; Chicago, Illinois. Abstract 342.
3. Boyle BA. Issues in antiretroviral therapy: When to start? AIDS Reader. 2001;11:66-70.
4. US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Washington, DC: DHHS; 2001. Published at: http://hivatis.org/trtgdlns.html.
5. Henry K. The case for more cautious, patient-focused antiretroviral therapy. Ann Intern Med. 2000;132:306-311.
6. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
7. Bangsberg DR, Hecht FM, Charlebois E, Chesney M, Moss AR. Comparing objective methods of adherence assessment: Electronic medication monitoring and unannounced pill count. AIDS & Behavior. 2000;5:275-281.
8. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33:1417-1423.
9. McNabb J. et al. Adherence to highly active antiretroviral therapy predicts outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis. 2001;33:700-705.
10. Matthews WC, et al. Predictors, prevalence, and therapeutic effect of early adherence after starting or changing antiretroviral therapy. AIDS Patient Care & STDs. In press.
11. Kasrissios H, Suárez JR, Katzenstein D, Girard P, Sheiner LB, Blaschke TF. Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS. 1998;12:2295-2303.
12. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134:968-977.
13. Thompson M, Gold M, Sathasivam K, et al. Adherence and relationship to antiretroviral efficacy in the H.E.A.R.T. (NZTA4006) study. In: Program and abstracts of the XIII International AIDS Conference; July 9-14, 2000; Durban, South Africa.
14. Bangsberg DR, Hecht FM, Clague H, et al. Provider assessment of adherence to HIV antiretroviral therapy. JAIDS. 2001;26:435-442.
15. Dunbar-Jacob J. Contributions to patient adherence: Is it time to share the blame? Health Psychology. 1993;12:91-92.
16. Sherbourne CD, Hays RD, Ordway L, et al. Antecedents of adherence to medical recommendations: results from the Medical Outcomes Study. J Behav Med. 1992;15:447-468.
17. Lerner BH, Gulick RM, Dubler NN. Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV disease. Ann Intern Med. 1998;129:573-578.
18. Fisher JD, Fisher WA. Changing AIDS risk behavior. Psychol Bull. 1992;111:455-474.
19. Fisher JD, Fisher WA, Misovich SJ, Kimble DL, Malloy TE. Changing AIDS risk behavior: effects of an intervention emphasizing AIDS risk reduction information, motivation, and behavioral skills in a college student population. Health Psychol. 1996;15:114-123.
20. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989;251:3273-3277.
21. Wagner GJ, Kanouse DE. Measuring the usual care control in adherence intervention trials. In: Programs and abstracts of the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract WePeB5813.
22. Wagner GJ, Rabkin JG. Measuring medication adherence: Is assessment of missed doses sufficient? AIDS. 1999;13:2491-2492.
23. Wagner GJ. Practice trials: a tool to assess adherence readiness among drug users. In: Programs and abstracts of the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract WePeB5814.
24. Mole L, Schmidgall D, Holodniy M. A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection. J Acquir Immune Defic Syndr. 2001;27:260-265.